Structure Therapeutics Aktie News

Structure Therapeutics' GLP-1 drug candidate, aleniglipron, has helped people lose up to 15% of their body weight. Its share price has tripled in the past year, suggesting investors have already priced approval into its valuation.

Structure Therapeutics CEO Ray Stevens talked about the biotech's path forward and his expectations for the future of the booming GLP-1 space.

In early December, over 50,000 shares of Structure Therapeutics were indirectly sold by a stakeholding company, valued at nearly $4 million. The stakeholding company is predominantly controlled by the Johnson family, who are highly active in the pharmaceutical sector.

Structure Therapeutics' positive phase 2 data for aleniglipron sent its stock price soaring last year. The medicine could join the fast-growing weight loss market, but it will face plenty of competition.

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each represent...

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary sh...

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.

Structure Therapeutics (GPCR) delivered robust Phase 2b results for aleniglipron, surpassing key efficacy and tolerability thresholds for oral GLP-1 therapies. GPCR now appears competitive with top oral obesity drugs, with dose optimization and front-end titration as critical levers for further differentiation. Recent $500M stock offering, combined with $800M cash, positions GPCR as 'Phase 3 re...